KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2017 - 2025)

Arbutus Biopharma's Non-Current Deffered Revenue history spans 12 years, with the latest figure at $2.9 million for Q1 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $2.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $2.9 million, a N/A change, with the full-year FY2024 number at $2.9 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $2.9 million in Q1 2025 for Arbutus Biopharma, roughly flat from $2.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for ABUS hit a ceiling of $15.6 million in Q1 2022 and a floor of $2.9 million in Q4 2024.
  • Historically, Non-Current Deffered Revenue has averaged $7.4 million across 4 years, with a median of $6.0 million in 2022.
  • The widest YoY moves for Non-Current Deffered Revenue: up 78.85% in 2023, down 78.85% in 2023.
  • Tracing ABUS's Non-Current Deffered Revenue over 4 years: stood at $6.0 million in 2022, then tumbled by 45.06% to $3.3 million in 2023, then decreased by 13.14% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ABUS at $2.9 million in Q1 2025, $2.9 million in Q4 2024, and $3.3 million in Q1 2023.